Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07411989

Shape-sensing Versus Electromagnetic Robotic Bronchoscopy for Evaluation of PulmoNary LEsions

This is an investigator-initiated, multicenter, non inferiority, cluster randomized controlled trial. The primary objective is to compare the diagnostic yield of the electromagnetic robotic assisted bronchoscopy with digital tomosynthesis (Galaxy system by Noah Medical) to the shape sensing robotic assisted bronchoscopy with integrated cone beam CT (Ion™ Endoluminal System by Intuitive) in patients undergoing bronchoscopy for peripheral pulmonary lesion (PPL) evaluation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rush University Medical Center, Chicago, Illinois, United States

Loading trial locations.

About this study

Millions of nodules are detected every year in the United States. The majority are benign, but some represent early lung cancer and biopsy is often needed to establish the diagnosis. Advanced imaging and navigational guidance systems are routinely used to sample these small peripheral lesions bronchoscopically.

A variety of navigational technologies are currently available, including non-robotic electromagnetic navigational bronchoscopy (ENB) and robotic assisted bronchoscopy (RAB), both cleared by the FDA via the 510(k) pathway. Since market release in 2019, few studies, mostly retrospective and observational studies have reported on the diagnostic yield of RAB which is estimated to be approximately 75-80%. Most of these procedures were performed using conventional fluoroscopy which provides a two-dimensional image to assist with location of the bronchoscope within the chest and with biopsy. However, pulmonary nodules are frequently not visible with conventional fluoroscopy, particularly subsolid or ground glass nodules, which may contribute to non-diagnostic procedures. Thus, the combination of RAB with CBCT, a three-dimensional cross-sectional imaging modality, has been widely adopted by the interventional pulmonology and advanced bronchoscopy community. Cone beam CT produces a near real-time intraprocedural CT image that allows the proceduralist to reposition the robotic bronchoscope based on the location of the bronchoscope relative to that of the nodule and minimize CT to body divergence (CT2BD). Preliminary data suggest that addition of CBCT improves the diagnostic yield. One of the RAB platforms (ssRAB by Intuitive) is now integrated with CBCT, which allows the proceduralist to update the position of the nodule in the navigation system itself. This upgrade is believed to increase the diagnostic yield of ssRAB.

The Galaxy System (Noah Medical) is the latest robotic bronchoscopy platform that integrates its digital tomosynthesis (DT) technology with electromagnetic navigation (EMN) robotic platform with continuous vision. DT is an imaging modality whereby a series of fluoroscopic digital images taken during a partial rotational sweep of a C-arm are superimposed and computationally processed to provide a final three-dimensional image in which the lesion of interest can be far more readily seen than by standard fluoroscopic screening whilst minimizing radiation exposure compared, for example, to CBCT. This new generation Image-Integrated Robotic Assisted Bronchoscopy (ii-RAB) utilizes the advantages of the stability of a robotic bronchoscopy and mitigates CT2BD with imaging confirmation that demonstrates the biopsy tool inside the lesion.

The current assumed pros of using the Galaxy system compared to ssRAB with integrated CBCT is that the procedure may be shorter in time with less use of radiation to the patient and staffs. While the potential downside of the use of DT only without CBCT is that it may be less accurate.

As there are no randomized or retrospective comparative data comparing the two robotic bronchoscopy platforms despite being commercially available and widely utilized, the investigators propose to compare the diagnostic yield of the newest electromagnetic RAB (E-RAB) with integrated digital tomosynthesis (DT) to that of ssRAB with integrated CBCT. Cleveland Clinic and RUSH University currently utilizes both E-RAB with DT and ssRAB with integrated CBCT and they are used interchangeably. Patients are typically assigned arbitrarily to procedures using either platform based on operating room availability.

Thus, the investigator proposes a randomized controlled study to test the hypothesis that the diagnostic yield of E-RAB with DT is not inferior to ssRAB with integrated CBCT in patients undergoing bronchoscopy to biopsy a PPL.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years of age at time of bronchoscopy
  • Scheduled for navigational bronchoscopy for the evaluation of pulmonary lesion

Exclusion criteria

  • Inability to provide informed consent

Treatment and study plan

Bronchoscopy for peripheral pulmonary lesion biopsy

Procedure

Participants are scheduled to undergo a bronchoscopy as part of their routine standard of care. Participants will be randomly assigned to one of our two standards of care bronchoscopy robotic platforms (Ion shape sensing robot or Galaxy by Noah electromagnetic robot).

Primary outcomes

  1. Diagnostic yield

    Time frame: 7 days post enrollment

    Diagnostic yield is defined as the proportion of procedures that results in acquisition of lesional tissue. Lesional tissue is defined by the presence of histopathological findings that readily explain the presence of a pulmonary lesion.

    The following common histopathological findings are pre-specified as lesional:

    i. Malignant ii. "Specific benign" findings accounting for the presence of a PPL

    • organizing pneumonia
    • purulence
    • granulomatous inflammation
    • hamartoma
    • amyloidoma Procedures with non-specific inflammation, normal tissue, atypia not diagnostic of malignancy, or where no biopsy is obtained due to navigation failure, complication, or equipment failure are non-diagnostic. Only guided bronchoscopy biopsies from the first target lesion are included; non-malignant samples are reviewed by a blinded panel.

Secondary outcomes

  1. Radiation Exposure During Study Bronchoscopy

    Time frame: During the bronchoscopy procedure

    Radiation exposure is defined as the radiation dose delivered to the patient during the study bronchoscopy, recorded as the dose area product (mGy·cm²). Only radiation directly associated with the index bronchoscopy procedure will be included.

Other outcomes

  1. Duration of Bronchoscopy

    Time frame: During the bronchoscopy procedure

    Duration of bronchoscopy is defined as the time (in minutes) from insertion of the robotic catheter into the endotracheal tube to removal of the catheter from the endotracheal tube after completion of the procedure.

  2. Need for Additional Diagnostic Procedures

    Time frame: 12 months

    This outcome is defined as any additional diagnostic procedure performed to evaluate the lung lesion of interest after the index bronchoscopy. Procedures include repeat bronchoscopy, transthoracic needle biopsy, or surgical lung biopsy.

  3. Diagnostic Accuracy at 12 Months Post-Bronchoscopy

    Time frame: 12 months

    Diagnostic accuracy is defined as the ability of the index bronchoscopy procedure to correctly identify the pathology of the target lung nodule, as confirmed by clinical follow-up, additional diagnostic procedures, or surgical pathology within 12 months after the biopsy. Both malignant and specific benign diagnoses will be included in the assessment of accuracy.

  4. Specimen Suitability for Molecular Analysis

    Time frame: Baseline and 1 year

    This outcome assesses whether tissue obtained during the index bronchoscopy procedure is adequate for molecular analysis when clinically indicated. Specimen suitability will be determined based on quantity, quality, and integrity of the tissue for intended molecular testing.

Study contacts

Contact information is provided by the study sponsor or research team.

See-Wei Low, MD

CONTACT

[email protected]

216 445-0570

Yvonne Meli, RN

CONTACT

[email protected]

216 445-4215

Sponsors and collaborators

Lead sponsor

The Cleveland Clinic

Other

Collaborators

  • Rush University Medical Center

Registry information

Official study title

Shape-sensing Versus Electromagnetic Robotic Bronchoscopy for Evaluation of PulmoNary LEsions: the SERENE Trial

Acronym: SERENE

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Feb 17, 2026
Registry last updated
May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.